: The Markey Cancer Center (MCC ) Clinical l Research and Data a Management Shared Resource Facility (CRD M SRF ) coordinates and facilitates clinical cancer trials at the MCC . The major goals of the shared resource are to provide support of the clinical trial process , including implementing and regulating trials provide a centralized clinical trial l database , and integrate with the following: investigational pharmacy support , financial accounting , data safety monitoring , and quality assurance . This shared resource also assist s physician investigators in the design and subsequent conduct of clinical l trials through its support of the Investigator Initiated Trial Protocol Development Unit . It performs all regulatory reporting and quality assurance needed to comply with Good Clinical Practice in the performance of clinical trials . The CRDM SRF has Standard Operating Procedures for all its activities including training of all new faculty an d staff . From Ma y 2011 through April 2012 , 2,54 2 new patient s with cancer were seen at the MCC . Of these , 1,45 1 were from Appalachian Kentucky . During the s time period , the CRDM SRF administrated therapeutic cancer clinical l trials that engage d 25 3 (10% ) participants in therapeutic intent clinical trials . Importantly , 14 1 Appalachian patient s were engage d in therapeutic intent clinical research , a 10 % accrual rate from these disadvantaged and unique.
The CRD M SR F provides central management an d oversight fo r coordinating , facilitating , and reporting on MCC cancer clinical trials . Th e CRDM SR F provides a central location for digital an d hard copy cancer protocols , a central database o f protocol-specific data , an update d lis t of active protocol s for investigators , an d protocol status reports . The CRDM SR F support s quality control functions , including education an d training service s for data managers and nurses and data auditing in support of the audit committee .
|Li, Jing; Song, Jun; Li, Xian et al. (2018) FFAR4 Is Involved in Regulation of Neurotensin Release From Neuroendocrine Cells and Male C57BL/6 Mice. Endocrinology 159:2939-2952|
|Rodriguez, Sharon D; Vanderford, Nathan L; Huang, Bin et al. (2018) A Social-Ecological Review of Cancer Disparities in Kentucky. South Med J 111:213-219|
|Chauhan, Aman; Yu, Qian; Ray, Neha et al. (2018) Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget 9:19245-19254|
|Huang, Bin; Pollock, Elizabeth; Zhu, Li et al. (2018) Ranking composite Cancer Burden Indices for geographic regions: point and interval estimates. Cancer Causes Control 29:279-287|
|Rea, Matthew; Gripshover, Tyler; Fondufe-Mittendorf, Yvonne (2018) Selective inhibition of CTCF binding by iAs directs TET-mediated reprogramming of 5-hydroxymethylation patterns in iAs-transformed cells. Toxicol Appl Pharmacol 338:124-133|
|Yarana, Chontida; Carroll, Dustin; Chen, Jing et al. (2018) Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury. Clin Cancer Res 24:1644-1653|
|Banerjee, Moumita; Cui, Xiaoyu; Li, Zhichuan et al. (2018) Na/K-ATPase Y260 Phosphorylation-mediated Src Regulation in Control of Aerobic Glycolysis and Tumor Growth. Sci Rep 8:12322|
|Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221|
|McKenna, Mary K; Noothi, Sunil K; Alhakeem, Sara S et al. (2018) Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. Blood 131:2943-2954|
|Jones, Derek; Bopaiah, Jeevith; Alghamedy, Fatemah et al. (2018) Polypharmacology Within the Full Kinome: a Machine Learning Approach. AMIA Jt Summits Transl Sci Proc 2017:98-107|
Showing the most recent 10 out of 359 publications